Fraser Finance

The Landbanking Group is a private company focused on enhancing the investment in natural capital through an eco-tech platform. It unites scientists, builders, technology experts, and investors to facilitate payments and investments that support environmental sustainability. The platform offers account documents and trade certificates that verify ecosystem outcomes, thereby creating market access in various natural markets. This innovative approach enables businesses and investors to establish natural capital accounts, fostering a more sustainable and responsible approach to environmental resources.

Therapixel SA is a French company specializing in the development of artificial intelligence-based medical image analytics software aimed at enhancing surgical procedures. Founded in 2013 and headquartered in Valbonne, France, Therapixel offers a range of products designed to assist healthcare professionals, including Radvise, an automatic image reading solution; Fluid, a touchless navigation system for surgical environments; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing outpatient imaging exams. The company's technology focuses on providing timely and relevant information to surgeons, ensuring they can access critical medical images before or during surgical operations. With additional locations in various countries, including Australia, China, and several nations across Europe and Latin America, Therapixel is committed to improving breast cancer detection and characterization through its innovative software solutions.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Incision is a developer of a medical education platform designed to provide a standardized approach to performing medical procedures through a series of practical steps and sub-steps. The platform facilitates access to shared experiences, skills, and expertise, enabling medical students to achieve rapid and thorough preparation for their roles in the operating room. By focusing on the development of essential competencies and skills, Incision aims to enhance the training of future healthcare professionals.

Spearad GmbH operates a multi-format platform designed for addressable television advertising, enabling broadcasters and over-the-top (OTT) content providers to effectively manage advertising campaigns. Founded in 2019 and headquartered in Frankfurt am Main, Germany, the company offers tools for media planning, central campaign management, and real-time reporting, facilitating the creation of flexible ad breaks and monetization plans. Spearad's integrated demand-side platform allows broadcasters to tap into a marketplace of advertising opportunities, enhancing their ability to deliver targeted ads. The technology supports various media formats, ensuring that television, OTT, and audio sectors can leverage digital advertising's benefits while accommodating the unique characteristics of each medium. With a global presence, including subsidiaries in the UK and the US, Spearad aims to transform the advertising landscape by offering solutions that respond to the evolving needs of advertisers and content providers.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Tessian Limited is a provider of an advanced email security platform that addresses human error in data handling, significantly reducing the risk of data loss. The platform employs machine learning and artificial intelligence to identify when emails are mistakenly sent to unintended recipients, alerting the sender in real time to allow corrections. It features tools such as CheckRecipient Guardian and CheckRecipient RuleBuilder, which enhance organizational control over email communications. Tessian’s technology is designed to analyze email networks and prevent the transmission of sensitive information to the wrong individuals, thereby safeguarding against threats like data exfiltration, business email compromise, and phishing attacks. The company serves various sectors, including legal services, healthcare, investment management, and technology. Founded in 2013 and headquartered in London, Tessian also has an office in San Francisco and is supported by prominent investors.

Clinical Genomics Pty Ltd. is a biotechnology company focused on the development and commercialization of diagnostic products for colorectal cancer (CRC). Based in North Ryde, Australia, with additional facilities in New Jersey and Sydney, the company offers innovative solutions such as Colvera, a blood test that monitors CRC recurrence by detecting methylated DNA from the BCAT1 and IKZF1 genes. Another product, InSure FIT, is a fecal immunochemical test designed to identify blood in stool samples. Founded in 2006, Clinical Genomics has established a solid intellectual property portfolio with over 20 patents. The company has formed a strategic alliance with Quest Diagnostics to enhance its market reach and impact in colorectal cancer screening and monitoring.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

ExThera Medical Corporation, founded in 2007 and located in Martinez, California, specializes in developing medical devices that address critical clinical challenges related to bloodstream infections and pathogen reduction in blood banking. The company's flagship product, the Seraph Microbind Affinity Blood Filter, effectively captures and eliminates a wide range of pathogens, including both drug-resistant bacteria and viruses, from human blood. This device utilizes the affinity of bacteria for immobilized heparin, a natural anticoagulant with additional beneficial properties, to reduce pathogen concentrations in the bloodstream. The Seraph filter not only acts as an adjunct to antibiotic therapy by lowering infection load and duration but also offers potential recovery support when effective drugs are unavailable. By providing a solution for treating conditions like bacteremia and enhancing blood safety during storage, ExThera Medical seeks to improve patient outcomes and address significant gaps in current medical treatments.

Tessian Limited is a provider of an advanced email security platform that addresses human error in data handling, significantly reducing the risk of data loss. The platform employs machine learning and artificial intelligence to identify when emails are mistakenly sent to unintended recipients, alerting the sender in real time to allow corrections. It features tools such as CheckRecipient Guardian and CheckRecipient RuleBuilder, which enhance organizational control over email communications. Tessian’s technology is designed to analyze email networks and prevent the transmission of sensitive information to the wrong individuals, thereby safeguarding against threats like data exfiltration, business email compromise, and phishing attacks. The company serves various sectors, including legal services, healthcare, investment management, and technology. Founded in 2013 and headquartered in London, Tessian also has an office in San Francisco and is supported by prominent investors.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Pole Star, established in 2002, is a leading developer of indoor location technology, operating in the United States and France. The company specializes in providing a comprehensive range of high-performance indoor location services, which include geofencing and analytics technology. Its innovative 3D system allows users to easily navigate and locate assets and people within various indoor environments, such as buildings, airports, malls, and convention centers. With a reach that spans over 100 million square feet of indoor space worldwide, Pole Star aims to enhance the operational efficiency and user experience for venue owners and mobile solution providers.